Genelux Investor Presentation Deck
"Allcomers" Approach May Reset Life Clock of Heavily Pre-treated Patients
While clinical remissions are obtainable, a majority of patients will relapse.
Genelux looks to take an all-comers approach
Key Trial Takeaways
Olvi-Vec addresses a
broad and underserved
pool of patients
●
Olvi-Vec trial inclusion
criteria allows patients
regardless of
(i) tumor biomarkers,
(ii) platinum refractory
tumors, or
(iii) number of prior lines of
treatment (i.e., no cap)
Olvi-Vec Phase 2 results
approach results in less
pre-treated platinum-
sensitive patients
GENELUX
GENELUX
100%
80%
60%
40%
20%
0%
Study
AURELIA¹
B-GEMOX²
FORWARD IF
VB-1114
JAVELIN-200
TOPACIOS
VIRO-15
OCEANS
GENELUX
RECIST1.1
# or prior lines
54%
≤2 prior lines
1-2 (21%), 3-4 (63%), ≥ 5 (16%)
Median 3 prior lines
≤ 3 prior lines
<3 prior lines
≤ 4 prior lines
Median 4 prior lines
GENELUX 85%
Regimen
Platinum-resistant / refractory patients
CA-125
(3)
(4)
Platinum-sensitive patients
Chemo + Avastin (i.e., CT+Bev)
Oxali + Gem + Avastin
Mirvetuximab soravtansine + pembrolizumab (median/high FRa group)
VB-111 + paclitaxel
Avelumab + PLD
Niraparib + pembrolizumab
Olvi-Vec / Chemo ± Avastin
No prior chemo in recurrent setting
References
(1) Pujade-Lauraine et al., J Clin Oncol 2014;32:1302-1308.
(2) Ikeda et al., Int J Gynecol Cancer 2013;23:355-360.
Footnote: As the data presented is based on a cross-trial comparison and not a head-to-head clinical trial, such comparisons may not be reliable due to differences in study protocols, conditions
and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other characteristics of our candidates compared to others presented.
Carbo + Gem + Avastin
GENELUX 77%
Matulonis et al., ESMO 2018.
Arend et al., Gynecol Oncol. 2020;157:578-584.
PFS-6-month
(5)
(6)
Konstantinopoulos et al., J Clin Oncol 2018;36(S15)106.
Aghajanian et al., Gynecol Oncol. 2015;139(1):10-16.
17View entire presentation